CD44：一个茎驱动器，调节器和标记 - 全部？
CD44: a stemness driver, regulator, and marker-all in one?
影响因子:3.60000
分区:医学3区 / 生物工程与应用微生物2区 细胞与组织工程3区 细胞生物学3区 血液学3区
发表日期:2024 Dec 06
作者:
Steffen J Sonnentag, Nagwa S M Ibrahim, Veronique Orian-Rousseau
摘要
尽管癌症干细胞的概念仍然存在争议，但先前的研究表明，在肿瘤生长开始期间，血液癌以及特定类型的固体癌症（例如结直肠癌）依赖于干细胞。此外，急性髓样白血病和大肠癌中对治疗治疗的耐药性可归因于少数具有称为最小残留疾病的干性特性的细胞群。在这篇综述中，我们回顾了癌症干细胞的发现以及血液癌中发现对固体癌症平行发现的贡献。我们专注于CD44作为干细胞标记物，无论是在血液癌和几种类型的固体癌中，尤其是胃肠道的固体癌症。这篇评论突出了新发现的CD44作用分子机制，这表明CD44确实在干性，干细胞维持和耐药性中具有功能。我们在这里试图建立CD44同工型在Stemness中的功能与它们参与肿瘤生长和转移的特定步骤之间的联系。©作者2024。由牛津大学出版社出版。版权所有。有关商业重复使用，请联系reprints@oup.com，以获取转载和翻译权以进行转载。所有其他权限都可以通过我们的restrimlink服务通过我们网站上文章页面上的“权限链接”获得 - 有关更多信息，请联系journals.permissions.permissions@oup.com。
Abstract
Although the concept of cancer stem cells is still controversial, previous studies have shown that blood cancers, as well as specific types of solid cancers such as colorectal cancer, rely on stem cells during the onset of tumor growth and further tumor development. Moreover, resistance to therapeutic treatment in leukemias such as acute myeloid leukemia and in colorectal cancer can be attributed to a small population of cells with stemness properties known as minimal residual disease. In this review, we look back on the discovery of cancer stem cells and the contribution of the findings in blood cancer to a parallel discovery in solid cancers. We focus on CD44 as a stem cell marker, both in blood cancers and in several types of solid cancers, particularly of the gastrointestinal tract. This review highlights newly discovered molecular mechanisms of action of CD44 which indicate that CD44 has indeed a function in stemness, stem cell maintenance, and drug resistance. We attempt here to make the link between the functions of CD44 isoforms in stemness and their involvement in specific steps of tumor growth and metastasis.© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.